Immune checkpoint inhibitors (ICIs) have revolutionized the current treatment landscape for
cancer, yet the response rates of ICIs remain unmet. Synergistic with immunotherapy, low …

Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment; yet their efficacy
remains variable across patients. This review delves into the intricate interplay of tumor …

Immune checkpoint inhibitors (ICI) are effective in cancer treatment. A pre-existing immune
response demonstrated by significant pretreatment tumor lymphocytic infiltration is a …

Therapeutic monoclonal antibodies blocking different immune checkpoints, have
demonstrated efficacy against a wide variety of solid tumors. The exclusion or absence of …

The development of immunotherapy, in particular immune checkpoint inhibitors (ICI), has
revolutionized cancer treatment in the past decades. However, its efficacy is still limited to …

In recent years, an increased understanding of T‐cell–regulatory mechanisms has led to the
development of a novel class of immune‐checkpoint inhibitors that have robust clinical …

Immunotherapy, particularly with immune checkpoint inhibitors, has significantly transformed
cancer treatment. Despite its success, many patients struggle to respond adequately or …

Since the approval of anti-CTLA4 therapy (ipilimumab) for late-stage melanoma in 2011, the
development of anticancer immunotherapy agents has thrived. The success of many …

The use of low-dose irradiation (LDI) for mobilizing innate and adaptive immunity is gaining
interest among the scientific community. Recent evidence suggests that LDI can …

The first evidence that radiotherapy enhances the efficacy of immune checkpoint blockers
(ICB) was obtained a dozen years ago in a mouse model of metastatic carcinoma refractory …